This observation is consistent with the hypothesized role of SF3B1 as a biomarker for immunotherapy currently under evaluation in a breast cancer clinical trial (44) but suggests that it may not generalize to additional cancer subtypes except for head and neck cancer. Here, SF3B1 is linked to head and neck cancer.